Gilead Sciences, Inc. — GILD

Close PriceMarket CapP/E RatioForward P/E RatioImplied Growth*Implied Forward Growth*DividendP/B Ratio
$118.84$147.60B18.416.010.4%8.9%$3.16
2.7%		6.9

Revenue & Net Income

Revenue & Net Income
  Date Revenue Net Income EPS Revenue Change Net Income Change EPS Change
0 2020-12-31 $24.7B $123.0M $0.10 N/A N/A N/A
1 2021-12-31 $27.3B $6.2B $4.96 10.6% 4961.0% 4860.0%
2 2022-12-31 $27.3B $4.6B $3.66 -0.1% -26.2% -26.2%
3 2023-12-31 $27.1B $5.7B $4.54 -0.6% 23.4% 24.0%
4 2024-12-31 $28.8B $480.0M $4.54 6.0% -91.5% 0.0%
5 TTM 2025-03-31 $22.1B $4.7B $4.76 -23.3% 868.8% 4.8%
6 Average -1.5% 1147.1% 972.5%

EPS

EPS

Forecasts

Revenue/Net Income Forecast EPS Forecast

Y/Y % Change

Revenue YoY Change EPS YoY Change
YoY Growth Rates

GILD Year-over-Year Growth

  2020 2021 2022 2023 2024 2025 2026 Average
Revenue Growth (%) 10.6% -0.1% -0.6% 6.0% 0.8% 3.5% 3.4%
Revenue Analysts (#) 0 0 0 0 0 7 7
EPS Growth (%) 4961.0% -26.2% 23.4% -91.5% 2006.2% 4.8% 1146.3%
EPS Analysts (#) 0 0 0 0 0 8 8

Expenses

Revenue vs Expenses Expenses % of Revenue
Year Revenue ($) Cost of Revenue ($) R&D ($) Sales & Marketing ($) G&A ($) SG&A ($) Facilities / D&A ($)
2021 $27.3B $4.6B $4.6B $5.2B $2.0B
2022 $27.3B $3.6B $5.0B $5.7B $2.1B
2023 $27.1B $3.8B $5.7B $6.1B $2.7B
2024 $28.8B $3.5B $5.9B $6.1B $2.8B
TTM $28.9B $3.4B $5.9B $1.6B $1.0B $6.0B $2.8B
Year Revenue Change (%) Cost of Revenue Change (%) R&D Change (%) SG&A Change (%) Facilities / D&A Change (%)
2022 -0.09 -21.91 8.17 8.14 2.59
2023 -0.60 7.06 14.89 7.35 28.06
2024 6.04 -8.44 3.31 0.02 2.75
TTM 0.38 -1.66 -0.02 -2.10 0.11
No unmapped expenses.

Segment Performance

axis1_GILD_Cell_Therapy_Products_Tecartus.png
axis1_GILD_Cell_Therapy_Products_Total_Cell_Therapy_Product_Sales.png
axis1_GILD_H_I_V_Product_Sales.png
axis1_GILD_H_I_V_Products_Biktarvy.png
axis1_GILD_H_I_V_Products_Descovy.png
axis1_GILD_H_I_V_Products_Genvoya.png
axis1_GILD_H_I_V_Products_Odefsey.png
axis1_GILD_H_I_V_Products_Other_H_I_V.png
axis1_GILD_H_I_V_Products_Symtuza_Revenue_Share.png
axis1_GILD_Liver_Disease.png
axis1_GILD_Liver_Disease_Products_Other_Liver_Disease.png
axis1_GILD_Liver_Disease_Products_Sofosbuvir_Velpatasvir.png
axis1_GILD_Liver_Disease_Products_Vemlidy.png
axis1_GILD_Oncology_Product.png
axis1_GILD_Other_Products_Am_Bisome.png
axis1_GILD_Other_Products_Other.png
axis1_GILD_Other_Products_Total_Other_Product_Sales.png
axis1_GILD_Other_Products_Yescarta.png
axis1_GILD_Product.png
axis1_GILD_Royalty_Contract_And_Other.png
axis1_GILD_Trodelvy.png
axis1_GILD_Veklury.png
SEGMENTS v2025-09-09 · 2025-11-10 08:22 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
Year Prod Rev Prod OI H I V Product Sales Rev H I V Product Sales OI H I V Products Biktarvy Rev H I V Products Biktarvy OI Oncology Product Rev Oncology Product OI Liver Disease Rev Liver Disease OI H I V Products Descovy Rev H I V Products Descovy OI Cell Therapy Products Total Cell Therapy Product Sales Rev Cell Therapy Products Total Cell Therapy Product Sales OI H I V Products Genvoya Rev H I V Products Genvoya OI Other Products Yescarta Rev Other Products Yescarta OI Royalty Contract And Other Rev Royalty Contract And Other OI Trodelvy Rev Trodelvy OI Liver Disease Products Sofosbuvir Velpatasvir Rev Liver Disease Products Sofosbuvir Velpatasvir OI H I V Products Odefsey Rev H I V Products Odefsey OI Liver Disease Products Vemlidy Rev Liver Disease Products Vemlidy OI Liver Disease Products Other Liver Disease Rev Liver Disease Products Other Liver Disease OI Other Products Total Other Product Sales Rev Other Products Total Other Product Sales OI Veklury Rev Veklury OI Other Products Am Bisome Rev Other Products Am Bisome OI H I V Products Symtuza Revenue Share Rev H I V Products Symtuza Revenue Share OI H I V Products Other H I V Rev H I V Products Other H I V OI Cell Therapy Products Tecartus Rev Cell Therapy Products Tecartus OI Other Products Other Rev Other Products Other OI Total Rev Total OI
2022 80.9B 0.00B 34.4B 0.00B 20.8B 0.00B 4.28B 0.00B 5.60B 0.00B 3.74B 0.00B 2.92B 0.00B 4.81B 0.00B 2.32B 0.00B 0.90B 0.00B 1.36B 0.00B 3.06B 0.00B 2.94B 0.00B 1.69B 0.00B 0.85B 0.00B 1.89B 0.00B 7.81B 0.00B 0.99B 0.00B 1.06B 0.00B 1.06B 0.00B 0.60B 0.00B 0.90B 0.00B 184.9B 0.00B
2023 80.8B 0.00B 36.4B 0.00B 23.7B 0.00B 5.86B 0.00B 5.57B 0.00B 3.97B 0.00B 3.74B 0.00B 4.12B 0.00B 3.00B 0.00B 0.55B 0.00B 2.12B 0.00B 3.07B 0.00B 2.70B 0.00B 1.72B 0.00B 0.77B 0.00B 1.72B 0.00B 4.37B 0.00B 0.98B 0.00B 1.06B 0.00B 0.80B 0.00B 0.74B 0.00B 0.73B 0.00B 188.5B 0.00B
2024 85.8B 0.00B 39.2B 0.00B 26.8B 0.00B 6.58B 0.00B 6.04B 0.00B 4.22B 0.00B 3.95B 0.00B 3.52B 0.00B 3.14B 0.00B 0.43B 0.00B 2.63B 0.00B 3.19B 0.00B 2.58B 0.00B 1.92B 0.00B 0.93B 0.00B 1.78B 0.00B 3.60B 0.00B 1.06B 0.00B 1.18B 0.00B 0.87B 0.00B 0.81B 0.00B 0.71B 0.00B 201.1B 0.00B
TTM 85.1B 0.00B 41.2B 0.00B 28.7B 0.00B 6.42B 0.00B 6.36B 0.00B 5.34B 0.00B 3.63B 0.00B 3.03B 0.00B 2.96B 0.00B 2.79B 0.00B 2.79B 0.00B 2.50B 0.00B 2.29B 0.00B 2.18B 0.00B 1.68B 0.00B 1.52B 0.00B 1.24B 0.00B 0.99B 0.00B 0.98B 0.00B 0.87B 0.00B 0.67B 0.00B 0.54B 0.00B 203.8B 0.00B
% of Total (TTM) 41.8% — 20.2% — 14.1% — 3.1% — 3.1% — 2.6% — 1.8% — 1.5% — 1.5% — 1.4% — 1.4% — 1.2% — 1.1% — 1.1% — 0.8% — 0.7% — 0.6% — 0.5% — 0.5% — 0.4% — 0.3% — 0.3% — 100% —
GILD_Europe_Member_axis2.png
GILD_Rest_Of_World_Member_axis2.png
GILD_U_S_axis2.png

No segment data available for GILD (axis 2).

Balance Sheet

Balance Sheet
  Metric Value
0 Total Assets $55,721M
1 Cash $5,144M
2 Total Liabilities $36,130M
3 Total Debt $24,946M
4 Total Equity $19,675M
5 Debt to Equity Ratio 1.27

EPS & Dividend

EPS & Dividend

Valuation

Valuation
Share Price Treasury Yield Estimates Fair Value (P/E) Fair Value (P/S) Current P/S Current P/E
$108.50 4.4% Nicks Growth: 2%
Nick's Expected Margin: 15%
FINVIZ Growth: 26%		 Nicks: 8
Finviz: 71		 Nick's: 1.180 4.7 22.8
Basis Year Nicks Valuation Nicks vs Share Price Finviz Valuation Finviz vs Share Price
$4.76 EPS TTM $37.43 -65.5% $338.55 212.0%
$7.92 EPS 2025 $62.28 -42.6% $563.30 419.2%
$8.48 EPS 2026 $66.68 -38.5% $603.13 455.9%

Implied Growth

Implied Growth
Average Median Std Dev Current Percentile
TTM Forward TTM Forward TTM Forward TTM Forward TTM Forward
Timeframe
1 Year 12.83% 8.64% 12.95% 8.56% 0.63% 0.32% 10.38% 8.90% 0.9% 78.7%
3 Years 12.83% 8.64% 12.95% 8.56% 0.63% 0.32% 10.38% 8.90% 0.9% 78.7%
5 Years 12.83% 8.64% 12.95% 8.56% 0.63% 0.32% 10.38% 8.90% 0.9% 78.7%
10 Years 12.83% 8.64% 12.95% 8.56% 0.63% 0.32% 10.38% 8.90% 0.9% 78.7%

← Back